Adjuvant treatment in non-small cell lung cancer: Where are we now?

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 4, Issue 6, 2006, Pages 595-600

  Juergens, Rosalyn A ^a,b   Brahmer, Julie R ^a,b  

^a Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ^*

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Adjuvant; Chemotherapy; Etoposide; Lung cancer; Platinum

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; MITOMYCIN C; NAVELBINE; PACLITAXEL; PLATINUM; UFT; VINBLASTINE; VINDESINE;

AREA UNDER THE CURVE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG FATALITY; HUMAN; ITALY; LEUKEMIA; LUNG NON SMALL CELL CANCER; META ANALYSIS; NORTH AMERICA; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 33747623281     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2006.0049     Document Type: Review

References (20)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. American Cancer Society. Estimated new cancer cases and deaths by sex for all sites, US, 2006. Available at: www.cancer.org. Accessed February 14, 2006.
3. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
4. Sandier AB, Gray R, Brahmer J, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865 ) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial-E4599 (abstract). J Clin Oncol 2005;23(16 suppl):LBA4.
5. Immerman SC, Vanecko RM, Fry WA, et al. Site of recurrence in patients with stages I and II carcinoma of the lung resected for cure. Ann Thorac Surg 1981;32:23-27.
6. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360.
7. Douillard JY, Rosell R, Delena M, et al. ANITA: phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association (abstract). J Clin Oncol 2005;23(16 suppl):7013.
8. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst 2003;95:1453-1461.
9. Strauss C, Herndon J, Maddaus M, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALBG) Protocol 9633. J Clin Oncol 2004;22(14 suppl):7019.
10. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352(25):2589-2597.
11. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
12. Postoperative radiotherapy in non-small-cell lung cancer: systemic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 1998;352:257-263.
13. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004;350:1713-1721.
14. Hamada C, Ohta M, Wada H, et al. Survival benefit oforal UFT for adjuvant chemotherapy after completely resected non-small-cell lung cancer. J Clin Oncol 2004;22:7002.
15. Hotta K, Matsuo K, Ueoka H, et al. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 2004;22:3860-3867.
16. Bria E, Gralla RJ, Raftopoulos H, et al. Does adjuvant chemotherapy improve survival in non small cell lung cancer (NSCLC)? A pooled-analysis of 6494 patients in 12 studies, examining survival and magnitude of benefit (abstract). J Clin Oncol 2005;23(16 suppl):7140.
17. Sedrakyan A, Van Der MJ, O'Byrne K, et al. Postoperative chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis. J Thorac Cardiovasc Surg 2004;128:414-419.
18. Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003;21:2004-2010.
19. Keller SM, Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 2000;343:1217-1222.
20. Mineo TC, Ambrogi V, Corsaro V, Roselli M. Postoperative adjuvant therapy for stage IB non-small-cell lung cancer. Eur J Cardiothorac Surg 2001;20:378-384.